Polpharma’s innovative child is ready to harvest
Jerzy Starak’s billions invested in Polpharma Biologics are going to soon bear fruit in the form of new biosimilar drugs.
Building an integrated biosimilars business
Polpharma Biologics is a fast-growing business that develops and manufactures
biopharmaceuticals as new molecular entities (NMEs) or biosimilars, and also
delivers biopharmaceutical CDMO services.
Press release 03.09.2019
Polpharma Biologics announces global commercialization deal for biosimilar natalizumab, a key multiple sclerosis medicine.
Metabolic control of CHOBC® for production of biologics
Process optimisation for biologics is obligatory for efficient processing and reduction
of Cost of Goods (COGs). Especially in the development of biosimilar antibodies, low COGs to
manufacture the antibody provides a competitive advantage compared to competing biosimilar
developers.